Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment.

Literature DB >> 20561789

Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment.

Abstract

Over the past few years a number of components of the PI3K/mTOR pathway have been the subject of intense drug discovery activities both in pharmaceutical companies and in academia. This review article summarizes progress made in the identification and development of allosteric and ATP-competitive kinase inhibitors of mTOR and their potential therapeutic use in oncology. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities: Disease Gene

Mesh：

Substances：

Year: 2010 PMID： 20561789 DOI： 10.1016/j.bmcl.2010.05.099

Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN： 0960-894X Impact factor: 2.823

Keyword Cloud
Cited

32 in total

1. An in silico protocol for identifying mTOR inhibitors from natural products.

Authors: Lei Chen; Ling Wang; Qiong Gu; Jun Xu
Journal: Mol Divers Date: 2014-08-26 Impact factor: 2.943

Review 2. mTOR function and therapeutic targeting in breast cancer.

Authors: Stephen H Hare; Amanda J Harvey
Journal: Am J Cancer Res Date: 2017-03-01 Impact factor: 6.166

3. A highly potent and selective Vps34 inhibitor alters vesicle trafficking and autophagy.

Authors: Baptiste Ronan; Odile Flamand; Lionel Vescovi; Christine Dureuil; Laurence Durand; Florence Fassy; Marie-France Bachelot; Annabelle Lamberton; Magali Mathieu; Thomas Bertrand; Jean-Pierre Marquette; Youssef El-Ahmad; Bruno Filoche-Romme; Laurent Schio; Carlos Garcia-Echeverria; Hélène Goulaouic; Benoit Pasquier
Journal: Nat Chem Biol Date: 2014-10-19 Impact factor: 15.040

Review 4. Toward rapamycin analog (rapalog)-based precision cancer therapy.

Authors: Ling-hua Meng; X F Steven Zheng
Journal: Acta Pharmacol Sin Date: 2015-08-24 Impact factor: 6.150

Review 5. mTOR kinase inhibitors as potential cancer therapeutic drugs.

Authors: Shi-Yong Sun
Journal: Cancer Lett Date: 2013-06-20 Impact factor: 8.679

6. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against osteosarcoma.

Authors: Yun-Rong Zhu; Han Min; Jian-Feng Fang; Feng Zhou; Xiong-Wei Deng; Yun-Qing Zhang
Journal: Cancer Biol Ther Date: 2015-04-14 Impact factor: 4.742

Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment.

1. An in silico protocol for identifying mTOR inhibitors from natural products.

Review 2. mTOR function and therapeutic targeting in breast cancer.

3. A highly potent and selective Vps34 inhibitor alters vesicle trafficking and autophagy.

Review 4. Toward rapamycin analog (rapalog)-based precision cancer therapy.

Review 5. mTOR kinase inhibitors as potential cancer therapeutic drugs.

6. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against osteosarcoma.

7. C6 ceramide sensitizes the anti-hepatocellular carcinoma (HCC) activity by AZD-8055, a novel mTORC1/2 dual inhibitor.

Review 8. Targeting the mTOR kinase domain: the second generation of mTOR inhibitors.

Review 9. mTOR Inhibitors in Castration-Resistant Prostate Cancer: A Systematic Review.

Review 10. Dysregulation of mRNA translation and energy metabolism in cancer.